Jason Gerberry
Stock Analyst at B of A Securities
(4.33)
# 377
Out of 5,239 analysts
158
Total ratings
63.33%
Success rate
12.19%
Average return
Main Sectors:
Stocks Rated by Jason Gerberry
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TEVA Teva Pharmaceutical Industries | Maintains: Buy | $38 → $42 | $35.84 | +17.19% | 16 | Apr 9, 2026 | |
| PFE Pfizer | Maintains: Neutral | $27 → $26 | $25.81 | +0.74% | 6 | Apr 9, 2026 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $100 → $111 | $75.38 | +47.25% | 8 | Apr 9, 2026 | |
| ALKS Alkermes | Maintains: Neutral | $34 → $36 | $35.47 | +1.49% | 11 | Apr 9, 2026 | |
| LLY Eli Lilly and Company | Maintains: Buy | $1,293 → $1,294 | $966.99 | +33.82% | 16 | Apr 2, 2026 | |
| LENZ LENZ Therapeutics | Maintains: Buy | $35 → $29 | $9.99 | +190.29% | 1 | Mar 25, 2026 | |
| JAZZ Jazz Pharmaceuticals | Maintains: Buy | $263 → $275 | $223.61 | +22.98% | 7 | Feb 25, 2026 | |
| HRMY Harmony Biosciences Holdings | Maintains: Underperform | $32 → $28 | $30.18 | -7.22% | 3 | Feb 25, 2026 | |
| ARWR Arrowhead Pharmaceuticals | Maintains: Buy | $62 → $81 | $77.74 | +4.19% | 4 | Dec 9, 2025 | |
| OCS Oculis Holding AG | Maintains: Buy | $30 → $29 | $32.65 | -11.18% | 4 | Nov 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $28 → $32 | $18.45 | +73.44% | 2 | Aug 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $33 → $30 | $29.06 | +3.23% | 6 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $50 → $49 | $9.08 | +439.65% | 2 | Aug 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $173 → $176 | $216.47 | -18.70% | 6 | Aug 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $3 → $1 | $1.77 | -43.50% | 4 | Jun 30, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $25 → $23 | $53.13 | -56.71% | 2 | Jun 11, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $45 → $46 | $49.71 | -7.46% | 3 | Jun 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $157 → $137 | $53.99 | +153.75% | 9 | Apr 1, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Underperform | $11 → $10 | $16.92 | -40.90% | 3 | Feb 28, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $30 | $31.15 | -3.69% | 2 | Jan 9, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $20 → $24 | $12.85 | +86.77% | 1 | Sep 10, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $56 | $55.78 | +0.39% | 2 | Jan 2, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $9 | $2.28 | +294.74% | 1 | Dec 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $37 → $25 | $13.33 | +87.55% | 3 | Oct 14, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $45 → $5 | $1.52 | +228.95% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underperform | $27 | $5.37 | +402.79% | 4 | Mar 24, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $20 | $1.95 | +925.64% | 1 | Jul 16, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $170 → $100 | $7.40 | +1,251.35% | 1 | Jul 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $95 | $202.78 | -53.15% | 10 | May 18, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Buy | $60 | $55.67 | +7.78% | 7 | Oct 17, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | $90 | $111.28 | -19.12% | 11 | Oct 17, 2019 |
Teva Pharmaceutical Industries
Apr 9, 2026
Maintains: Buy
Price Target: $38 → $42
Current: $35.84
Upside: +17.19%
Pfizer
Apr 9, 2026
Maintains: Neutral
Price Target: $27 → $26
Current: $25.81
Upside: +0.74%
Ionis Pharmaceuticals
Apr 9, 2026
Maintains: Buy
Price Target: $100 → $111
Current: $75.38
Upside: +47.25%
Alkermes
Apr 9, 2026
Maintains: Neutral
Price Target: $34 → $36
Current: $35.47
Upside: +1.49%
Eli Lilly and Company
Apr 2, 2026
Maintains: Buy
Price Target: $1,293 → $1,294
Current: $966.99
Upside: +33.82%
LENZ Therapeutics
Mar 25, 2026
Maintains: Buy
Price Target: $35 → $29
Current: $9.99
Upside: +190.29%
Jazz Pharmaceuticals
Feb 25, 2026
Maintains: Buy
Price Target: $263 → $275
Current: $223.61
Upside: +22.98%
Harmony Biosciences Holdings
Feb 25, 2026
Maintains: Underperform
Price Target: $32 → $28
Current: $30.18
Upside: -7.22%
Arrowhead Pharmaceuticals
Dec 9, 2025
Maintains: Buy
Price Target: $62 → $81
Current: $77.74
Upside: +4.19%
Oculis Holding AG
Nov 13, 2025
Maintains: Buy
Price Target: $30 → $29
Current: $32.65
Upside: -11.18%
Aug 26, 2025
Maintains: Neutral
Price Target: $28 → $32
Current: $18.45
Upside: +73.44%
Aug 12, 2025
Maintains: Buy
Price Target: $33 → $30
Current: $29.06
Upside: +3.23%
Aug 12, 2025
Maintains: Buy
Price Target: $50 → $49
Current: $9.08
Upside: +439.65%
Aug 5, 2025
Maintains: Buy
Price Target: $173 → $176
Current: $216.47
Upside: -18.70%
Jun 30, 2025
Downgrades: Underperform
Price Target: $3 → $1
Current: $1.77
Upside: -43.50%
Jun 11, 2025
Maintains: Buy
Price Target: $25 → $23
Current: $53.13
Upside: -56.71%
Jun 5, 2025
Maintains: Neutral
Price Target: $45 → $46
Current: $49.71
Upside: -7.46%
Apr 1, 2025
Maintains: Buy
Price Target: $157 → $137
Current: $53.99
Upside: +153.75%
Feb 28, 2025
Maintains: Underperform
Price Target: $11 → $10
Current: $16.92
Upside: -40.90%
Jan 9, 2025
Reiterates: Buy
Price Target: $30
Current: $31.15
Upside: -3.69%
Sep 10, 2024
Maintains: Buy
Price Target: $20 → $24
Current: $12.85
Upside: +86.77%
Jan 2, 2024
Maintains: Buy
Price Target: $52 → $56
Current: $55.78
Upside: +0.39%
Dec 12, 2022
Downgrades: Underperform
Price Target: $9
Current: $2.28
Upside: +294.74%
Oct 14, 2022
Downgrades: Underperform
Price Target: $37 → $25
Current: $13.33
Upside: +87.55%
Dec 2, 2021
Downgrades: Underperform
Price Target: $45 → $5
Current: $1.52
Upside: +228.95%
Mar 24, 2021
Downgrades: Underperform
Price Target: $27
Current: $5.37
Upside: +402.79%
Jul 16, 2020
Initiates: Neutral
Price Target: $20
Current: $1.95
Upside: +925.64%
Jul 15, 2020
Downgrades: Neutral
Price Target: $170 → $100
Current: $7.40
Upside: +1,251.35%
May 18, 2020
Reinstates: Neutral
Price Target: $95
Current: $202.78
Upside: -53.15%
Oct 17, 2019
Reinstates: Buy
Price Target: $60
Current: $55.67
Upside: +7.78%
Oct 17, 2019
Reinstates: Neutral
Price Target: $90
Current: $111.28
Upside: -19.12%